nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Faecal incontinence—Niacin—atherosclerosis	0.0193	0.0225	CcSEcCtD
Regadenoson—Adenosine triphosphate—ABCG1—atherosclerosis	0.0183	0.417	CrCbGaD
Regadenoson—Adenosine triphosphate—HSPA1B—atherosclerosis	0.0139	0.316	CrCbGaD
Regadenoson—Feeling hot—Niacin—atherosclerosis	0.0124	0.0145	CcSEcCtD
Regadenoson—Musculoskeletal pain—Lovastatin—atherosclerosis	0.0115	0.0134	CcSEcCtD
Regadenoson—Musculoskeletal pain—Pravastatin—atherosclerosis	0.00972	0.0113	CcSEcCtD
Regadenoson—Pain in extremity—Lovastatin—atherosclerosis	0.00824	0.00961	CcSEcCtD
Regadenoson—Atrial fibrillation—Simvastatin—atherosclerosis	0.00814	0.00949	CcSEcCtD
Regadenoson—Pain in extremity—Ezetimibe—atherosclerosis	0.00808	0.00943	CcSEcCtD
Regadenoson—Atrial fibrillation—Niacin—atherosclerosis	0.00747	0.00871	CcSEcCtD
Regadenoson—Abdominal discomfort—Lovastatin—atherosclerosis	0.00683	0.00796	CcSEcCtD
Regadenoson—Adenosine triphosphate—ABCA1—atherosclerosis	0.00679	0.154	CrCbGaD
Regadenoson—ADORA2A—Monoamine Transport—TNFRSF11B—atherosclerosis	0.0065	0.0659	CbGpPWpGaD
Regadenoson—Abdominal discomfort—Simvastatin—atherosclerosis	0.00639	0.00745	CcSEcCtD
Regadenoson—Abdominal distension—Niacin—atherosclerosis	0.00616	0.00718	CcSEcCtD
Regadenoson—Abdominal distension—Pravastatin—atherosclerosis	0.00606	0.00707	CcSEcCtD
Regadenoson—Angina pectoris—Niacin—atherosclerosis	0.00596	0.00695	CcSEcCtD
Regadenoson—Mental disorder—Rosuvastatin—atherosclerosis	0.00589	0.00687	CcSEcCtD
Regadenoson—Angina pectoris—Pravastatin—atherosclerosis	0.00587	0.00684	CcSEcCtD
Regadenoson—Connective tissue disorder—Ezetimibe—atherosclerosis	0.0055	0.00641	CcSEcCtD
Regadenoson—Angioedema—Rosuvastatin—atherosclerosis	0.00535	0.00624	CcSEcCtD
Regadenoson—Acute coronary syndrome—Pravastatin—atherosclerosis	0.00529	0.00618	CcSEcCtD
Regadenoson—Flushing—Lovastatin—atherosclerosis	0.00529	0.00617	CcSEcCtD
Regadenoson—Myocardial infarction—Pravastatin—atherosclerosis	0.00527	0.00614	CcSEcCtD
Regadenoson—Flushing—Ezetimibe—atherosclerosis	0.00519	0.00605	CcSEcCtD
Regadenoson—Cough—Rosuvastatin—atherosclerosis	0.00511	0.00596	CcSEcCtD
Regadenoson—Angiopathy—Ezetimibe—atherosclerosis	0.00507	0.00592	CcSEcCtD
Regadenoson—Immune system disorder—Ezetimibe—atherosclerosis	0.00505	0.00589	CcSEcCtD
Regadenoson—Mediastinal disorder—Ezetimibe—atherosclerosis	0.00504	0.00588	CcSEcCtD
Regadenoson—Arthralgia—Rosuvastatin—atherosclerosis	0.00499	0.00582	CcSEcCtD
Regadenoson—Myalgia—Rosuvastatin—atherosclerosis	0.00499	0.00582	CcSEcCtD
Regadenoson—Adenosine triphosphate—AKT1—atherosclerosis	0.00498	0.113	CrCbGaD
Regadenoson—Flushing—Simvastatin—atherosclerosis	0.00495	0.00577	CcSEcCtD
Regadenoson—Mental disorder—Ezetimibe—atherosclerosis	0.0049	0.00571	CcSEcCtD
Regadenoson—Hypoaesthesia—Niacin—atherosclerosis	0.00487	0.00568	CcSEcCtD
Regadenoson—Erythema—Ezetimibe—atherosclerosis	0.00487	0.00568	CcSEcCtD
Regadenoson—Dysgeusia—Lovastatin—atherosclerosis	0.00486	0.00567	CcSEcCtD
Regadenoson—Hypoaesthesia—Pravastatin—atherosclerosis	0.0048	0.0056	CcSEcCtD
Regadenoson—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00469	0.00547	CcSEcCtD
Regadenoson—Vision blurred—Lovastatin—atherosclerosis	0.00468	0.00546	CcSEcCtD
Regadenoson—Mental disorder—Simvastatin—atherosclerosis	0.00467	0.00545	CcSEcCtD
Regadenoson—Tremor—Lovastatin—atherosclerosis	0.00465	0.00542	CcSEcCtD
Regadenoson—Erythema—Simvastatin—atherosclerosis	0.00464	0.00541	CcSEcCtD
Regadenoson—Ill-defined disorder—Lovastatin—atherosclerosis	0.00461	0.00537	CcSEcCtD
Regadenoson—Eye disorder—Niacin—atherosclerosis	0.00458	0.00534	CcSEcCtD
Regadenoson—Tinnitus—Niacin—atherosclerosis	0.00457	0.00533	CcSEcCtD
Regadenoson—Dysgeusia—Simvastatin—atherosclerosis	0.00455	0.0053	CcSEcCtD
Regadenoson—Flushing—Niacin—atherosclerosis	0.00455	0.0053	CcSEcCtD
Regadenoson—Angioedema—Lovastatin—atherosclerosis	0.00454	0.00529	CcSEcCtD
Regadenoson—Ill-defined disorder—Ezetimibe—atherosclerosis	0.00452	0.00527	CcSEcCtD
Regadenoson—Tinnitus—Pravastatin—atherosclerosis	0.0045	0.00524	CcSEcCtD
Regadenoson—Malaise—Lovastatin—atherosclerosis	0.00448	0.00522	CcSEcCtD
Regadenoson—Flushing—Pravastatin—atherosclerosis	0.00448	0.00522	CcSEcCtD
Regadenoson—Cardiac disorder—Pravastatin—atherosclerosis	0.00448	0.00522	CcSEcCtD
Regadenoson—Angioedema—Ezetimibe—atherosclerosis	0.00445	0.00519	CcSEcCtD
Regadenoson—Angiopathy—Niacin—atherosclerosis	0.00444	0.00518	CcSEcCtD
Regadenoson—Malaise—Ezetimibe—atherosclerosis	0.00439	0.00512	CcSEcCtD
Regadenoson—Vision blurred—Simvastatin—atherosclerosis	0.00438	0.0051	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00436	0.00508	CcSEcCtD
Regadenoson—Tremor—Simvastatin—atherosclerosis	0.00435	0.00507	CcSEcCtD
Regadenoson—Insomnia—Rosuvastatin—atherosclerosis	0.00432	0.00504	CcSEcCtD
Regadenoson—Ill-defined disorder—Simvastatin—atherosclerosis	0.00431	0.00502	CcSEcCtD
Regadenoson—Palpitations—Ezetimibe—atherosclerosis	0.0043	0.00502	CcSEcCtD
Regadenoson—Paraesthesia—Rosuvastatin—atherosclerosis	0.00429	0.00501	CcSEcCtD
Regadenoson—Erythema—Niacin—atherosclerosis	0.00426	0.00497	CcSEcCtD
Regadenoson—Cough—Ezetimibe—atherosclerosis	0.00425	0.00495	CcSEcCtD
Regadenoson—Angioedema—Simvastatin—atherosclerosis	0.00424	0.00495	CcSEcCtD
Regadenoson—Arthralgia—Lovastatin—atherosclerosis	0.00423	0.00493	CcSEcCtD
Regadenoson—Myalgia—Lovastatin—atherosclerosis	0.00423	0.00493	CcSEcCtD
Regadenoson—Chest pain—Lovastatin—atherosclerosis	0.00423	0.00493	CcSEcCtD
Regadenoson—Anxiety—Lovastatin—atherosclerosis	0.00421	0.00491	CcSEcCtD
Regadenoson—Hypertension—Ezetimibe—atherosclerosis	0.0042	0.0049	CcSEcCtD
Regadenoson—Malaise—Simvastatin—atherosclerosis	0.00419	0.00488	CcSEcCtD
Regadenoson—Discomfort—Lovastatin—atherosclerosis	0.00418	0.00487	CcSEcCtD
Regadenoson—Arthralgia—Ezetimibe—atherosclerosis	0.00414	0.00483	CcSEcCtD
Regadenoson—Chest pain—Ezetimibe—atherosclerosis	0.00414	0.00483	CcSEcCtD
Regadenoson—Myalgia—Ezetimibe—atherosclerosis	0.00414	0.00483	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00412	0.0048	CcSEcCtD
Regadenoson—Dysgeusia—Pravastatin—atherosclerosis	0.00411	0.00479	CcSEcCtD
Regadenoson—Discomfort—Ezetimibe—atherosclerosis	0.0041	0.00478	CcSEcCtD
Regadenoson—Pain—Rosuvastatin—atherosclerosis	0.00409	0.00477	CcSEcCtD
Regadenoson—Anaphylactic shock—Lovastatin—atherosclerosis	0.00405	0.00472	CcSEcCtD
Regadenoson—Vision blurred—Niacin—atherosclerosis	0.00402	0.00469	CcSEcCtD
Regadenoson—Anaphylactic shock—Ezetimibe—atherosclerosis	0.00397	0.00463	CcSEcCtD
Regadenoson—Vision blurred—Pravastatin—atherosclerosis	0.00396	0.00461	CcSEcCtD
Regadenoson—Arthralgia—Simvastatin—atherosclerosis	0.00395	0.00461	CcSEcCtD
Regadenoson—Chest pain—Simvastatin—atherosclerosis	0.00395	0.00461	CcSEcCtD
Regadenoson—Myalgia—Simvastatin—atherosclerosis	0.00395	0.00461	CcSEcCtD
Regadenoson—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00394	0.00459	CcSEcCtD
Regadenoson—Anxiety—Simvastatin—atherosclerosis	0.00394	0.00459	CcSEcCtD
Regadenoson—Tremor—Pravastatin—atherosclerosis	0.00393	0.00459	CcSEcCtD
Regadenoson—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00391	0.00456	CcSEcCtD
Regadenoson—Discomfort—Simvastatin—atherosclerosis	0.00391	0.00455	CcSEcCtD
Regadenoson—Nervous system disorder—Ezetimibe—atherosclerosis	0.0039	0.00454	CcSEcCtD
Regadenoson—Angioedema—Niacin—atherosclerosis	0.0039	0.00454	CcSEcCtD
Regadenoson—Ill-defined disorder—Pravastatin—atherosclerosis	0.00389	0.00454	CcSEcCtD
Regadenoson—Skin disorder—Ezetimibe—atherosclerosis	0.00386	0.0045	CcSEcCtD
Regadenoson—Angioedema—Pravastatin—atherosclerosis	0.00384	0.00447	CcSEcCtD
Regadenoson—Syncope—Niacin—atherosclerosis	0.00382	0.00446	CcSEcCtD
Regadenoson—Urticaria—Rosuvastatin—atherosclerosis	0.0038	0.00443	CcSEcCtD
Regadenoson—Anaphylactic shock—Simvastatin—atherosclerosis	0.00379	0.00442	CcSEcCtD
Regadenoson—Malaise—Pravastatin—atherosclerosis	0.00379	0.00441	CcSEcCtD
Regadenoson—Abdominal pain—Rosuvastatin—atherosclerosis	0.00378	0.00441	CcSEcCtD
Regadenoson—Palpitations—Niacin—atherosclerosis	0.00377	0.00439	CcSEcCtD
Regadenoson—Loss of consciousness—Niacin—atherosclerosis	0.00375	0.00437	CcSEcCtD
Regadenoson—Cough—Niacin—atherosclerosis	0.00372	0.00434	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00369	0.0043	CcSEcCtD
Regadenoson—Insomnia—Lovastatin—atherosclerosis	0.00366	0.00427	CcSEcCtD
Regadenoson—Cough—Pravastatin—atherosclerosis	0.00366	0.00427	CcSEcCtD
Regadenoson—Paraesthesia—Lovastatin—atherosclerosis	0.00364	0.00424	CcSEcCtD
Regadenoson—Myalgia—Niacin—atherosclerosis	0.00363	0.00423	CcSEcCtD
Regadenoson—Arthralgia—Niacin—atherosclerosis	0.00363	0.00423	CcSEcCtD
Regadenoson—Hypertension—Pravastatin—atherosclerosis	0.00362	0.00423	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00362	0.00422	CcSEcCtD
Regadenoson—Dyspnoea—Lovastatin—atherosclerosis	0.00361	0.00421	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.0036	0.0042	CcSEcCtD
Regadenoson—Insomnia—Ezetimibe—atherosclerosis	0.00359	0.00419	CcSEcCtD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—SIRT1—atherosclerosis	0.00358	0.0363	CbGpPWpGaD
Regadenoson—Myalgia—Pravastatin—atherosclerosis	0.00357	0.00417	CcSEcCtD
Regadenoson—Chest pain—Pravastatin—atherosclerosis	0.00357	0.00417	CcSEcCtD
Regadenoson—Arthralgia—Pravastatin—atherosclerosis	0.00357	0.00417	CcSEcCtD
Regadenoson—Paraesthesia—Ezetimibe—atherosclerosis	0.00357	0.00416	CcSEcCtD
Regadenoson—Anxiety—Pravastatin—atherosclerosis	0.00356	0.00415	CcSEcCtD
Regadenoson—Dyspnoea—Ezetimibe—atherosclerosis	0.00354	0.00413	CcSEcCtD
Regadenoson—Discomfort—Pravastatin—atherosclerosis	0.00353	0.00412	CcSEcCtD
Regadenoson—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00352	0.00411	CcSEcCtD
Regadenoson—Anaphylactic shock—Niacin—atherosclerosis	0.00348	0.00406	CcSEcCtD
Regadenoson—Pain—Lovastatin—atherosclerosis	0.00346	0.00404	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00345	0.00403	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00343	0.004	CcSEcCtD
Regadenoson—Asthenia—Rosuvastatin—atherosclerosis	0.00343	0.004	CcSEcCtD
Regadenoson—Insomnia—Simvastatin—atherosclerosis	0.00343	0.004	CcSEcCtD
Regadenoson—Anaphylactic shock—Pravastatin—atherosclerosis	0.00343	0.004	CcSEcCtD
Regadenoson—Shock—Niacin—atherosclerosis	0.00342	0.00399	CcSEcCtD
Regadenoson—Paraesthesia—Simvastatin—atherosclerosis	0.0034	0.00397	CcSEcCtD
Regadenoson—Pain—Ezetimibe—atherosclerosis	0.0034	0.00396	CcSEcCtD
Regadenoson—Tachycardia—Niacin—atherosclerosis	0.0034	0.00396	CcSEcCtD
Regadenoson—Skin disorder—Niacin—atherosclerosis	0.00338	0.00394	CcSEcCtD
Regadenoson—Dyspnoea—Simvastatin—atherosclerosis	0.00338	0.00394	CcSEcCtD
Regadenoson—Hyperhidrosis—Niacin—atherosclerosis	0.00336	0.00392	CcSEcCtD
Regadenoson—Feeling abnormal—Lovastatin—atherosclerosis	0.00334	0.00389	CcSEcCtD
Regadenoson—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00331	0.00386	CcSEcCtD
Regadenoson—Hyperhidrosis—Pravastatin—atherosclerosis	0.00331	0.00386	CcSEcCtD
Regadenoson—Feeling abnormal—Ezetimibe—atherosclerosis	0.00327	0.00382	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00327	0.00382	CcSEcCtD
Regadenoson—Diarrhoea—Rosuvastatin—atherosclerosis	0.00327	0.00381	CcSEcCtD
Regadenoson—Hypotension—Niacin—atherosclerosis	0.00325	0.00379	CcSEcCtD
Regadenoson—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00325	0.00379	CcSEcCtD
Regadenoson—Pain—Simvastatin—atherosclerosis	0.00324	0.00378	CcSEcCtD
Regadenoson—Urticaria—Lovastatin—atherosclerosis	0.00322	0.00375	CcSEcCtD
Regadenoson—Abdominal pain—Lovastatin—atherosclerosis	0.0032	0.00373	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00317	0.0037	CcSEcCtD
Regadenoson—Dizziness—Rosuvastatin—atherosclerosis	0.00316	0.00369	CcSEcCtD
Regadenoson—Urticaria—Ezetimibe—atherosclerosis	0.00316	0.00368	CcSEcCtD
Regadenoson—Insomnia—Niacin—atherosclerosis	0.00315	0.00367	CcSEcCtD
Regadenoson—Abdominal pain—Ezetimibe—atherosclerosis	0.00314	0.00366	CcSEcCtD
Regadenoson—Paraesthesia—Niacin—atherosclerosis	0.00312	0.00364	CcSEcCtD
Regadenoson—Feeling abnormal—Simvastatin—atherosclerosis	0.00312	0.00364	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00312	0.00364	CcSEcCtD
Regadenoson—Dyspnoea—Niacin—atherosclerosis	0.0031	0.00362	CcSEcCtD
Regadenoson—Gastrointestinal pain—Simvastatin—atherosclerosis	0.0031	0.00361	CcSEcCtD
Regadenoson—Insomnia—Pravastatin—atherosclerosis	0.0031	0.00361	CcSEcCtD
Regadenoson—Somnolence—Niacin—atherosclerosis	0.00309	0.00361	CcSEcCtD
Regadenoson—Paraesthesia—Pravastatin—atherosclerosis	0.00308	0.00359	CcSEcCtD
Regadenoson—Dyspnoea—Pravastatin—atherosclerosis	0.00305	0.00356	CcSEcCtD
Regadenoson—ADORA2A—Monoamine Transport—AGT—atherosclerosis	0.00302	0.0307	CbGpPWpGaD
Regadenoson—Rash—Rosuvastatin—atherosclerosis	0.00301	0.00352	CcSEcCtD
Regadenoson—Dermatitis—Rosuvastatin—atherosclerosis	0.00301	0.00351	CcSEcCtD
Regadenoson—Urticaria—Simvastatin—atherosclerosis	0.00301	0.00351	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Niacin—atherosclerosis	0.003	0.0035	CcSEcCtD
Regadenoson—Abdominal pain—Simvastatin—atherosclerosis	0.003	0.00349	CcSEcCtD
Regadenoson—Headache—Rosuvastatin—atherosclerosis	0.00299	0.00349	CcSEcCtD
Regadenoson—Hypersensitivity—Lovastatin—atherosclerosis	0.00298	0.00348	CcSEcCtD
Regadenoson—Pain—Niacin—atherosclerosis	0.00298	0.00347	CcSEcCtD
Regadenoson—Pain—Pravastatin—atherosclerosis	0.00293	0.00342	CcSEcCtD
Regadenoson—Hypersensitivity—Ezetimibe—atherosclerosis	0.00293	0.00341	CcSEcCtD
Regadenoson—Asthenia—Lovastatin—atherosclerosis	0.00291	0.00339	CcSEcCtD
Regadenoson—Asthenia—Ezetimibe—atherosclerosis	0.00285	0.00332	CcSEcCtD
Regadenoson—Gastrointestinal pain—Niacin—atherosclerosis	0.00285	0.00332	CcSEcCtD
Regadenoson—Nausea—Rosuvastatin—atherosclerosis	0.00284	0.00331	CcSEcCtD
Regadenoson—Feeling abnormal—Pravastatin—atherosclerosis	0.00282	0.00329	CcSEcCtD
Regadenoson—Gastrointestinal pain—Pravastatin—atherosclerosis	0.0028	0.00327	CcSEcCtD
Regadenoson—Hypersensitivity—Simvastatin—atherosclerosis	0.00279	0.00326	CcSEcCtD
Regadenoson—Diarrhoea—Lovastatin—atherosclerosis	0.00277	0.00323	CcSEcCtD
Regadenoson—Urticaria—Niacin—atherosclerosis	0.00276	0.00322	CcSEcCtD
Regadenoson—Abdominal pain—Niacin—atherosclerosis	0.00275	0.00321	CcSEcCtD
Regadenoson—Urticaria—Pravastatin—atherosclerosis	0.00272	0.00317	CcSEcCtD
Regadenoson—Asthenia—Simvastatin—atherosclerosis	0.00272	0.00317	CcSEcCtD
Regadenoson—Diarrhoea—Ezetimibe—atherosclerosis	0.00272	0.00317	CcSEcCtD
Regadenoson—Abdominal pain—Pravastatin—atherosclerosis	0.00271	0.00316	CcSEcCtD
Regadenoson—Dizziness—Lovastatin—atherosclerosis	0.00268	0.00312	CcSEcCtD
Regadenoson—Dizziness—Ezetimibe—atherosclerosis	0.00263	0.00306	CcSEcCtD
Regadenoson—Diarrhoea—Simvastatin—atherosclerosis	0.00259	0.00302	CcSEcCtD
Regadenoson—Vomiting—Lovastatin—atherosclerosis	0.00258	0.003	CcSEcCtD
Regadenoson—Hypersensitivity—Niacin—atherosclerosis	0.00256	0.00299	CcSEcCtD
Regadenoson—Rash—Lovastatin—atherosclerosis	0.00255	0.00298	CcSEcCtD
Regadenoson—Dermatitis—Lovastatin—atherosclerosis	0.00255	0.00298	CcSEcCtD
Regadenoson—Headache—Lovastatin—atherosclerosis	0.00254	0.00296	CcSEcCtD
Regadenoson—Vomiting—Ezetimibe—atherosclerosis	0.00253	0.00295	CcSEcCtD
Regadenoson—Hypersensitivity—Pravastatin—atherosclerosis	0.00252	0.00294	CcSEcCtD
Regadenoson—Dizziness—Simvastatin—atherosclerosis	0.00251	0.00292	CcSEcCtD
Regadenoson—Rash—Ezetimibe—atherosclerosis	0.00251	0.00292	CcSEcCtD
Regadenoson—Dermatitis—Ezetimibe—atherosclerosis	0.0025	0.00292	CcSEcCtD
Regadenoson—Asthenia—Niacin—atherosclerosis	0.0025	0.00291	CcSEcCtD
Regadenoson—Headache—Ezetimibe—atherosclerosis	0.00249	0.0029	CcSEcCtD
Regadenoson—Asthenia—Pravastatin—atherosclerosis	0.00246	0.00287	CcSEcCtD
Regadenoson—Vomiting—Simvastatin—atherosclerosis	0.00241	0.00281	CcSEcCtD
Regadenoson—Nausea—Lovastatin—atherosclerosis	0.00241	0.00281	CcSEcCtD
Regadenoson—Rash—Simvastatin—atherosclerosis	0.00239	0.00279	CcSEcCtD
Regadenoson—Dermatitis—Simvastatin—atherosclerosis	0.00239	0.00278	CcSEcCtD
Regadenoson—Diarrhoea—Niacin—atherosclerosis	0.00238	0.00278	CcSEcCtD
Regadenoson—Headache—Simvastatin—atherosclerosis	0.00237	0.00277	CcSEcCtD
Regadenoson—Nausea—Ezetimibe—atherosclerosis	0.00236	0.00275	CcSEcCtD
Regadenoson—Diarrhoea—Pravastatin—atherosclerosis	0.00234	0.00273	CcSEcCtD
Regadenoson—Dizziness—Niacin—atherosclerosis	0.0023	0.00268	CcSEcCtD
Regadenoson—Dizziness—Pravastatin—atherosclerosis	0.00227	0.00264	CcSEcCtD
Regadenoson—Nausea—Simvastatin—atherosclerosis	0.00225	0.00262	CcSEcCtD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—SERPINE1—atherosclerosis	0.00221	0.0225	CbGpPWpGaD
Regadenoson—Vomiting—Niacin—atherosclerosis	0.00221	0.00258	CcSEcCtD
Regadenoson—Rash—Niacin—atherosclerosis	0.00219	0.00256	CcSEcCtD
Regadenoson—Dermatitis—Niacin—atherosclerosis	0.00219	0.00256	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Other—EDNRA—atherosclerosis	0.00219	0.0222	CbGpPWpGaD
Regadenoson—Headache—Niacin—atherosclerosis	0.00218	0.00254	CcSEcCtD
Regadenoson—Vomiting—Pravastatin—atherosclerosis	0.00218	0.00254	CcSEcCtD
Regadenoson—Rash—Pravastatin—atherosclerosis	0.00216	0.00252	CcSEcCtD
Regadenoson—Dermatitis—Pravastatin—atherosclerosis	0.00216	0.00252	CcSEcCtD
Regadenoson—Headache—Pravastatin—atherosclerosis	0.00215	0.0025	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—HRH1—atherosclerosis	0.00213	0.0216	CbGpPWpGaD
Regadenoson—Nausea—Niacin—atherosclerosis	0.00207	0.00241	CcSEcCtD
Regadenoson—Nausea—Pravastatin—atherosclerosis	0.00203	0.00237	CcSEcCtD
Regadenoson—ADORA2A—Monoamine Transport—IL1B—atherosclerosis	0.00189	0.0192	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—HRH1—atherosclerosis	0.00183	0.0185	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—UTS2—atherosclerosis	0.00168	0.017	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—AHR—atherosclerosis	0.00153	0.0156	CbGpPWpGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—VEGFA—atherosclerosis	0.00152	0.0155	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—CST3—atherosclerosis	0.00141	0.0144	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—HRH1—atherosclerosis	0.00139	0.0141	CbGpPWpGaD
Regadenoson—ADORA2A—Monoamine Transport—TNF—atherosclerosis	0.00137	0.0139	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—NAMPT—atherosclerosis	0.00134	0.0136	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL4—atherosclerosis	0.00132	0.0134	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—CX3CR1—atherosclerosis	0.00132	0.0134	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—F7—atherosclerosis	0.00127	0.0129	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—CNR2—atherosclerosis	0.00122	0.0124	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—UTS2—atherosclerosis	0.00118	0.0119	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—GHRL—atherosclerosis	0.00113	0.0115	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CX3CR1—atherosclerosis	0.00113	0.0114	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CX3CL1—atherosclerosis	0.00111	0.0112	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—ADIPOQ—atherosclerosis	0.0011	0.0111	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CNR2—atherosclerosis	0.00105	0.0106	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CCL4—atherosclerosis	0.001	0.0102	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—CCR2—atherosclerosis	0.000951	0.00966	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—EDNRA—atherosclerosis	0.000951	0.00966	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL3—atherosclerosis	0.000901	0.00915	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—UTS2—atherosclerosis	0.000896	0.00909	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—SIRT1—atherosclerosis	0.000863	0.00876	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CX3CR1—atherosclerosis	0.000859	0.00871	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CASR—atherosclerosis	0.000859	0.00871	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CX3CL1—atherosclerosis	0.000842	0.00855	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCR2—atherosclerosis	0.000815	0.00827	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—EDNRA—atherosclerosis	0.000815	0.00827	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—AGTR1—atherosclerosis	0.000809	0.00821	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CNR2—atherosclerosis	0.000798	0.0081	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—GHRL—atherosclerosis	0.000794	0.00806	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—PRKCG—atherosclerosis	0.00079	0.00802	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—HRH1—atherosclerosis	0.000785	0.00797	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PRKCG—atherosclerosis	0.000775	0.00786	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—PPARA—atherosclerosis	0.000718	0.00728	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—HRH1—atherosclerosis	0.000713	0.00724	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PDGFB—atherosclerosis	0.000698	0.00709	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—KNG1—atherosclerosis	0.000697	0.00708	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—AGTR1—atherosclerosis	0.000693	0.00703	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CCL3—atherosclerosis	0.000686	0.00697	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—LEP—atherosclerosis	0.000681	0.00691	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—NOS2—atherosclerosis	0.000635	0.00644	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CCR2—atherosclerosis	0.000621	0.0063	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—EDNRA—atherosclerosis	0.000621	0.0063	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—GHRL—atherosclerosis	0.000605	0.00614	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PRKCG—atherosclerosis	0.000596	0.00605	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—PPARG—atherosclerosis	0.000593	0.00602	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—EDN1—atherosclerosis	0.000588	0.00596	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL5—atherosclerosis	0.000583	0.00592	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PDGFB—atherosclerosis	0.000537	0.00545	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—SERPINE1—atherosclerosis	0.000534	0.00542	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—KNG1—atherosclerosis	0.000531	0.00539	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—AGTR1—atherosclerosis	0.000528	0.00536	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCL4—atherosclerosis	0.000516	0.00523	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—UTS2—atherosclerosis	0.000506	0.00514	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—AGT—atherosclerosis	0.000488	0.00495	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CASR—atherosclerosis	0.000485	0.00492	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—UTS2—atherosclerosis	0.00046	0.00466	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CNR2—atherosclerosis	0.000451	0.00458	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	0.000451	0.00457	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—EDN1—atherosclerosis	0.000447	0.00454	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CCL5—atherosclerosis	0.000444	0.00451	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CX3CR1—atherosclerosis	0.000441	0.00447	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CASR—atherosclerosis	0.000441	0.00447	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CX3CL1—atherosclerosis	0.000432	0.00439	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HRH1—atherosclerosis	0.000421	0.00428	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CNR2—atherosclerosis	0.00041	0.00416	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	0.000402	0.00408	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—MAPK8—atherosclerosis	0.000398	0.00404	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—AGT—atherosclerosis	0.000371	0.00377	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—STAT3—atherosclerosis	0.000357	0.00362	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCL3—atherosclerosis	0.000352	0.00357	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—EDNRA—atherosclerosis	0.000351	0.00356	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CCR2—atherosclerosis	0.000351	0.00356	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—F2—atherosclerosis	0.000343	0.00348	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GHRL—atherosclerosis	0.000342	0.00347	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAPK3—atherosclerosis	0.000341	0.00346	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APOA4—atherosclerosis	0.000331	0.00336	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—EDNRA—atherosclerosis	0.000319	0.00323	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCR2—atherosclerosis	0.000319	0.00323	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	0.000318	0.00322	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GHRL—atherosclerosis	0.00031	0.00315	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CCL2—atherosclerosis	0.000306	0.0031	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—NFKB1—atherosclerosis	0.000305	0.0031	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCL4—atherosclerosis	0.000305	0.00309	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MAPK8—atherosclerosis	0.0003	0.00305	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—KNG1—atherosclerosis	0.0003	0.00305	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AGTR1—atherosclerosis	0.000298	0.00303	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APOA2—atherosclerosis	0.000285	0.00289	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—STAT3—atherosclerosis	0.000275	0.00279	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—KNG1—atherosclerosis	0.000272	0.00277	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—UTS2—atherosclerosis	0.000271	0.00276	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AGTR1—atherosclerosis	0.000271	0.00275	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MAPK3—atherosclerosis	0.000262	0.00266	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CX3CR1—atherosclerosis	0.00026	0.00264	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CASR—atherosclerosis	0.00026	0.00264	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CX3CL1—atherosclerosis	0.000255	0.00259	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—IL6—atherosclerosis	0.000254	0.00258	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—EDN1—atherosclerosis	0.000253	0.00257	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CCL5—atherosclerosis	0.000251	0.00255	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—atherosclerosis	0.000249	0.00253	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CNR2—atherosclerosis	0.000242	0.00246	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CXCL8—atherosclerosis	0.000242	0.00245	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MMP3—atherosclerosis	0.000241	0.00245	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PRKCG—atherosclerosis	0.000239	0.00242	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—atherosclerosis	0.00023	0.00233	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—EDN1—atherosclerosis	0.00023	0.00233	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCL5—atherosclerosis	0.000228	0.00231	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PRKCG—atherosclerosis	0.000217	0.0022	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—VWF—atherosclerosis	0.000216	0.00219	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APOC3—atherosclerosis	0.000214	0.00218	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LDLR—atherosclerosis	0.000213	0.00216	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AGT—atherosclerosis	0.00021	0.00213	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCL3—atherosclerosis	0.000208	0.00211	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NCF1—atherosclerosis	0.000199	0.00202	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—F2—atherosclerosis	0.000194	0.00197	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IL6—atherosclerosis	0.000192	0.00195	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AGT—atherosclerosis	0.000191	0.00193	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EDNRA—atherosclerosis	0.000188	0.00191	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCR2—atherosclerosis	0.000188	0.00191	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CYBA—atherosclerosis	0.000187	0.0019	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CG—atherosclerosis	0.000186	0.00188	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PLAT—atherosclerosis	0.000183	0.00186	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PARP1—atherosclerosis	0.000183	0.00186	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GHRL—atherosclerosis	0.000183	0.00186	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—AKT1—atherosclerosis	0.000177	0.0018	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—F2—atherosclerosis	0.000176	0.00179	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CG—atherosclerosis	0.000169	0.00171	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KNG1—atherosclerosis	0.000161	0.00163	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AGTR1—atherosclerosis	0.00016	0.00162	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCL2—atherosclerosis	0.000157	0.00159	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PLG—atherosclerosis	0.000156	0.00158	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SOCS3—atherosclerosis	0.000148	0.0015	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MMP3—atherosclerosis	0.000143	0.00145	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IGF2—atherosclerosis	0.000142	0.00144	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APOB—atherosclerosis	0.000138	0.0014	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CXCL8—atherosclerosis	0.000137	0.00139	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EDN1—atherosclerosis	0.000136	0.00138	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCL5—atherosclerosis	0.000135	0.00137	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LPL—atherosclerosis	0.000132	0.00134	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRKCG—atherosclerosis	0.000128	0.0013	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SPP1—atherosclerosis	0.000125	0.00127	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CXCL8—atherosclerosis	0.000124	0.00126	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PDGFB—atherosclerosis	0.000115	0.00117	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AGT—atherosclerosis	0.000113	0.00114	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APOE—atherosclerosis	0.00011	0.00112	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LEP—atherosclerosis	0.00011	0.00112	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CAV1—atherosclerosis	0.000109	0.00111	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APOA1—atherosclerosis	0.000109	0.00111	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ESR1—atherosclerosis	0.000105	0.00107	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—F2—atherosclerosis	0.000104	0.00106	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CG—atherosclerosis	9.96e-05	0.00101	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MAPK3—atherosclerosis	9.54e-05	0.000968	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—INS—atherosclerosis	9.43e-05	0.000956	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCL2—atherosclerosis	9.27e-05	0.000941	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IGF1—atherosclerosis	9.12e-05	0.000925	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SERPINE1—atherosclerosis	8.66e-05	0.000879	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NOS3—atherosclerosis	8.27e-05	0.000839	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CXCL8—atherosclerosis	7.33e-05	0.000744	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AKT1—atherosclerosis	7.08e-05	0.000719	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL6—atherosclerosis	6.97e-05	0.000708	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MMP9—atherosclerosis	6.63e-05	0.000673	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NFKB1—atherosclerosis	6.56e-05	0.000666	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAPK8—atherosclerosis	6.45e-05	0.000654	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AKT1—atherosclerosis	6.43e-05	0.000653	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—VEGFA—atherosclerosis	5.95e-05	0.000604	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—STAT3—atherosclerosis	5.9e-05	0.000598	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAPK3—atherosclerosis	5.63e-05	0.000572	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TGFB1—atherosclerosis	5.47e-05	0.000555	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL6—atherosclerosis	4.12e-05	0.000418	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKT1—atherosclerosis	3.8e-05	0.000386	CbGpPWpGaD
